ChemoCentryx
CCXI
$51.99
Share price
0.00%
Change (1 day)
33.72%
Change (1 year)
Categories
P/S ratio for ChemoCentryx (CCXI)
P/S ratio as of May 2024 (TTM): 101
According to ChemoCentryx's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 100.514. At the end of 2022 the company had a P/S ratio of 47.5.
P/S ratio history for ChemoCentryx from 2012 to 2022
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2022 | 47.5 | -40.54% |
| 2021 | 79.9 | 20.11% |
| 2020 | 66.6 | 0.44% |
| 2019 | 66.3 | 414.1% |
| 2018 | 12.9 | 266.45% |
| 2017 | 3.52 | -88.63% |
| 2016 | 30.9 | |
| 2015 | N/A | |
| 2014 | N/A | -100% |
| 2013 | 41.0 | -44.17% |
| 2012 | 73.4 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 4.06 | -95.96% | 🇺🇸 USA |
 Pfizer PFE | 2.75 | -97.26% | 🇺🇸 USA |
 AbbVie ABBV | 5.24 | -94.78% | 🇺🇸 USA |
 Amgen AMGN | 5.87 | -94.16% | 🇺🇸 USA |
 Biogen BIIB | 3.40 | -96.62% | 🇺🇸 USA |
 Merck MRK | 5.45 | -94.58% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.01 | -98.00% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.40 | -97.61% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | 1.21 | -98.80% | 🇮🇱 Israel |